China’s National Medical Products Administration approved two differentiated therapies aimed at acute and seasonal disease burdens. Everest Medicines’ Cardamyst, an at-home nasal spray for paroxysmal supraventricular tachycardia, was cleared as a self-administered option, while Simcere’s Yingmule received approval as a long-acting monoclonal antibody to prevent RSV-related lower respiratory tract infections in newborns and infants. The approvals expand differentiated care models toward outpatient administration for rhythm issues and strengthen passive immunization coverage entering RSV seasons. For manufacturers and partners, they signal continued regulatory support for longer-acting antibody strategies in respiratory pediatrics. In market terms, the clearances broaden product categories beyond traditional hospital-administered therapies and may impact how companies plan next RSV seasons and pediatric immunization portfolios.